Understand how libido, erections and sexual satisfaction differ, where testosterone fits, and why assessment looks beyond a single symptom or blood test.
Do changes in libido or erections mean low testosterone? Not necessarily: European Association of Urology (EAU) guidance assesses desire and erection problems separately, with hormone findings interpreted alongside symptoms and health history.
This article is for informational purposes only and is not medical advice. Personal symptoms and decisions about testing or treatment belong in a conversation with a qualified clinician.
Sexual desire, also called libido, means interest in sex. Erectile function concerns getting and maintaining an erection. These are related parts of sexual function, but the EAU recommends asking about them separately.
Its erectile-dysfunction guidance also calls for separate questions about arousal, ejaculation and orgasm. A useful description therefore starts with the particular experience that has changed rather than the broad statement that sexual function is worse.
The distinctions can be organized like this:
The EAU defines erectile dysfunction as a persistent inability to attain and maintain an erection sufficient for satisfactory sexual performance. The word persistent matters. That definition does not turn every occasional erection difficulty into a diagnosis.
For a clinical conversation, describing the affected area is more precise than using libido as a catch-all term. It gives the clinician a clearer starting point for the detailed sexual history recommended by the guideline.
No. The assessment tools recommended by the EAU treat erectile function and satisfaction as distinct domains. They also distinguish intercourse satisfaction from overall satisfaction.
This distinction prevents a narrow reading of sexual health. An assessment that asks only about erection firmness does not cover everything those tools are designed to measure. Desire and orgasmic function also have their own place in the assessment.
A clinician may therefore ask separate questions about:
These questions are not different ways of asking for the same answer. They describe separate outcomes that should remain separate when discussing symptoms or evaluating treatment.
The practical point is to name dissatisfaction directly if that is the concern. Translating every change in satisfaction into an erection problem or a testosterone problem loses information that the EAU's assessment framework deliberately preserves.
The EAU's male-hypogonadism guideline identifies reduced libido, erectile dysfunction and fewer spontaneous or morning erections as more-specific sexual symptoms of late-onset hypogonadism. Hypogonadism is the condition being assessed when symptoms suggest testosterone deficiency.
The same guideline classifies reduced intercourse or masturbation frequency and delayed ejaculation as less-specific sexual symptoms. That distinction gives some symptoms greater diagnostic relevance without making a symptom list a diagnosis.
The evidence boundary is important here: the EAU's diagnostic approach combines compatible symptoms or signs with biochemical evidence of low testosterone. A symptom's association with hypogonadism does not establish that hormones explain an individual's experience.
Morning erections belong in this discussion because the erectile-dysfunction guideline specifically recommends asking about them. It also asks about erection rigidity and duration. Those details form part of the sexual history rather than a stand-alone home test of hormone status.
For more context on how sexual symptoms fit into a hormone assessment, keep the distinction between an associated symptom and a confirmed condition in view.
Testing should establish whether the biochemical findings fit the clinical concern. The EAU's male-hypogonadism guideline calls for compatible signs or symptoms together with low morning total testosterone confirmed on at least two occasions.
The guideline recommends reliable assays and fasting measurements. Its stated morning testing window is between 07:00 and 10:00. These are elements of the guideline's diagnostic process, not a personal testing plan for every reader with a sexual concern.
The erectile-dysfunction guideline also includes early-morning fasting total testosterone in its assessment. It notes that bioavailable or calculated free testosterone may sometimes help corroborate the total testosterone measurement.
That makes the question more specific than simply asking whether a number is low. The clinician is considering the measurement alongside the symptoms and deciding whether additional hormone information is needed.
Useful questions for that discussion include:
Our explanation of the language used for total and free measurements offers background for that conversation. The decision about which measurements matter in an individual case remains clinical.
Because the EAU evaluates erectile dysfunction as more than a hormone question. Its framework includes medical and sexual history, a focused physical examination and laboratory assessment.
The guideline describes diagnostic approaches that can help distinguish vascular, hormonal or psychogenic contributors. Vascular refers to blood vessels. Psychogenic refers to psychological contributors rather than a hormone measurement alone.
The recommended examination covers several systems:
The EAU also recommends assessing blood pressure and heart rate. Body mass index or waist circumference forms another part of the assessment.
Laboratory evaluation includes fasting blood glucose or HbA1c and a lipid profile if those measures have not been assessed in the previous 12 months. Total testosterone is included as well. Together, these recommendations show why an erection concern may lead to questions and tests beyond a testosterone panel.
The cardiovascular connection deserves attention without alarmist language. The EAU treats erectile dysfunction as a cardiovascular-risk concern and recommends cardiovascular risk assessment when the problem is predominantly vasculogenic, meaning related to blood vessels.
The guideline also notes that clinical and biochemical evaluation may identify coexisting conditions even when it does not establish the exact cause of erectile dysfunction. The purpose is therefore broader than finding a single explanation for one symptom.
The EAU's male-hypogonadism guidance says testosterone therapy can improve libido and milder forms of erectile dysfunction in men with hypogonadism. It also lists possible improvements in intercourse frequency, orgasm and overall satisfaction.
The population boundary is essential: these findings concern men with hypogonadism. They are not evidence that testosterone therapy is appropriate for every man with erection difficulty or dissatisfaction.
The erectile-dysfunction guideline likewise places testosterone therapy within clinical assessment. It says therapy may be considered when clinically indicated for men with low or low-normal testosterone and accompanying problems with desire, erectile function or dissatisfaction.
A useful treatment discussion keeps the intended outcome specific. Improving desire is not the same outcome as improving erection function. Overall satisfaction is another outcome again.
This is why the original symptom description remains relevant after testing. It defines what the clinician and patient are discussing rather than treating every aspect of sexual function as one interchangeable measure. Decisions about treatment require qualified care rather than a symptom-based assumption.
The EAU's framework brings the separate domains back together through a detailed history, examination and appropriate testing. Separating symptoms is the starting point, not the end of the evaluation.
For the reader, the most useful preparation is a clear account of the concern. The guideline-supported areas to describe include:
A physician can then consider those details alongside medical history and the examination. Hormone findings sit within that assessment, while metabolic or cardiovascular findings may direct attention to broader health questions.
Reading about the broader role of hormone testing can help clarify the terminology before an appointment. The aim is not to arrive with a self-diagnosis. It is to make the actual change easier to discuss and to understand why the assessment may cover more than testosterone.
The central distinction is straightforward: wanting sex, having an erection and feeling satisfied are not the same measure. Keeping those experiences separate makes the clinical question more precise.
The next conversation can focus on which domain has changed and how that change fits the health history and test findings. That is a more useful starting point than asking a testosterone result to explain every aspect of sexual function.
How might future research improve the way clinicians connect changes in desire, erections and satisfaction with hormone findings and treatment outcomes?
The physician assessing a sexual concern handles the medical interpretation; Testostra helps men understand the hormone terminology surrounding that work. Articles on total testosterone and free testosterone address confusion about SHBG and related biomarkers, giving readers clearer language for a clinical conversation rather than an individual diagnosis or treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra